Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine + Sintilimab + S-1 for advanced pancreatic cancer
ChiCTR1900025112Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Oncorine, sintilimab and tegafur in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Clinical efficacy and assessment of adverse events. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
Oncorinesintilimabtegafur
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1900025112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025112.